✦ LIBER ✦

Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen

✍ Scribed by Nazli Gad-El-Mawla; M. Hani Hussein; S. Abdel-Hadi; O. El-Taneer; Melissa Adde; Ian Magrath

Publisher: Springer
Year: 1989
Tongue: English
Weight: 312 KB
Volume: 24
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00253233

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity and preliminary results with a

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas

✍ M. A. Fridrik; H. Hausmaninger; G. Michlmayr; R. Haidinger; H. L. Seewann; M. Le 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views

A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non-Hodgkin's lymphoma. To date eight Austrian centres entered 37 patients in thi

Results of a BFM-based protocol for the

Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-Acute lymphoblastic leukemia in Argentina

✍ Chantada, Guillermo Luis; Felice, Maria Sara; Zubizarreta, Pedro Alberto; Diaz, 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 3 views

## Purpose: To report the feasibility and results of a study based on the bfm-all. nhl/86 protocol for b-non-hodgin's lymphoma (nhl) and b-acute lymphoblastic leukemia (b-all) in argentina. design. prospective, single arm, non-randomized trial. ## Patients and methods: From august 1988 to decembe

Phase II cooperative study with a new al

Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas

✍ Gherlinzoni, F. ;Mazza, P. ;Zinzani, P. L. ;Tura, S. ;Lanza, F. ;Castoldi, G. ;B 📂 Article 📅 1990 🏛 Springer-Verlag ⚖ 563 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa